P-610 Growth inhibition of NSCLC xenografts by erlotinib is independent of HER1/2 overexpression and can reliably be monitored by serum tumor markers
Authors:
- Thomas FriessTFThomas Friess
- Rolf JuchemRJRolf Juchem
- Werner ScheuerWSWerner Scheuer
- Max HasmannMHMax Hasmann
- 1 August 2003
- journal article
- abstracts
- Published by Elsevier in Lung Cancer
- Vol. 41, S246